The Effects of Biocompatible Compared with Standard Peritoneal Dialysis Solutions on Peritonitis Microbiology, Treatment, and Outcomes: the balANZ Trial

• Published in: Peritoneal dialysis international Vol. 32; no. 5; pp. 497 - 506
• Main Authors: JOHNSON, David W, BROWN, Fiona G, SCHOLLUM, John, SURANYI, Michael G, TAN, Seng H, VOSS, David, CLARKE, Margaret, BOUDVILLE, Neil, ELIAS, Tony J, FOO, Marjorie W. Y, JONES, Bernard, KULKARNI, Hemant, LANGHAM, Robyn, RANGANATHAN, Dwarakanathan
• Format: Journal Article
• Language: English
• Published: Milton, ON Multimed Inc 01.09.2012; Multimed
• Subjects: Adult; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Anti-Bacterial Agents; Australia; Biocompatible Materials - pharmacology; Biological and medical sciences; Dialysis Solutions - chemistry; Dialysis Solutions - pharmacology; Emergency and intensive care: renal failure. Dialysis management; Female; Hospitalization; Humans; Hydrogen-Ion Concentration; Intensive care medicine; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - microbiology; Kidney Failure, Chronic - therapy; Male; Medical sciences; New Zealand; Original; Peritoneal Dialysis - adverse effects; Peritoneal Dialysis - methods; Peritoneum - drug effects; Peritoneum - microbiology; Peritonitis - drug therapy; Peritonitis - epidemiology; Peritonitis - microbiology; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the urinary system; Survival Rate; Treatment Outcome; New Zealand; Australia; Kidney disease; Urinary system disease; Prognosis; Microbiology; Terminal stage; Glucose; technique survival; end-stage renal disease; glucose degradation products; Survival; Peritoneal dialysis; randomized controlled trial; Extrarenal dialysis; Treatment; outcomes; Abdominal disease; Renal failure; Biocompatibility; Degradation product; Peritonitis

A multicenter, multi-country randomized controlled trial (the balANZ study) recently reported that peritonitis rates significantly improved with the use of neutral-pH peritoneal dialysis (PD) solutions low in glucose degradation products ("biocompatible") compared with standard solutions....